These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27457255)

  • 1. Long-term Follow-up of Patients With Retinitis Pigmentosa Receiving Intraocular Ciliary Neurotrophic Factor Implants.
    Birch DG; Bennett LD; Duncan JL; Weleber RG; Pennesi ME
    Am J Ophthalmol; 2016 Oct; 170():10-14. PubMed ID: 27457255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa.
    Birch DG; Weleber RG; Duncan JL; Jaffe GJ; Tao W;
    Am J Ophthalmol; 2013 Aug; 156(2):283-292.e1. PubMed ID: 23668681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal study of cone photoreceptors during retinal degeneration and in response to ciliary neurotrophic factor treatment.
    Talcott KE; Ratnam K; Sundquist SM; Lucero AS; Lujan BJ; Tao W; Porco TC; Roorda A; Duncan JL
    Invest Ophthalmol Vis Sci; 2011 Apr; 52(5):2219-26. PubMed ID: 21087953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dose-dependent macular thickness changes assessed by fd-oct in patients with retinitis pigmentosa treated with ciliary neurotrophic factor.
    Pilli S; Zawadzki RJ; Telander DG
    Retina; 2014 Jul; 34(7):1384-90. PubMed ID: 24368307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ciliary neurotrophic factor for macular telangiectasia type 2: results from a phase 1 safety trial.
    Chew EY; Clemons TE; Peto T; Sallo FB; Ingerman A; Tao W; Singerman L; Schwartz SD; Peachey NS; Bird AC;
    Am J Ophthalmol; 2015 Apr; 159(4):659-666.e1. PubMed ID: 25528956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Ciliary Neurotrophic Factor on Retinal Neurodegeneration in Patients with Macular Telangiectasia Type 2: A Randomized Clinical Trial.
    Chew EY; Clemons TE; Jaffe GJ; Johnson CA; Farsiu S; Lad EM; Guymer R; Rosenfeld P; Hubschman JP; Constable I; Wiley H; Singerman LJ; Gillies M; Comer G; Blodi B; Eliott D; Yan J; Bird A; Friedlander M;
    Ophthalmology; 2019 Apr; 126(4):540-549. PubMed ID: 30292541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of subtenon-injected autologous platelet-rich plasma on visual functions in eyes with retinitis pigmentosa: preliminary clinical results.
    Arslan U; Özmert E; Demirel S; Örnek F; Şermet F
    Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):893-908. PubMed ID: 29546474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fourier-domain optical coherence tomography and microperimetry findings in retinitis pigmentosa.
    Lupo S; Grenga PL; Vingolo EM
    Am J Ophthalmol; 2011 Jan; 151(1):106-11. PubMed ID: 21094934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease course of patients with X-linked retinitis pigmentosa due to RPGR gene mutations.
    Sandberg MA; Rosner B; Weigel-DiFranco C; Dryja TP; Berson EL
    Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1298-304. PubMed ID: 17325176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing residual visual function in severe vision loss.
    Ayton LN; Apollo NV; Varsamidis M; Dimitrov PN; Guymer RH; Luu CD
    Invest Ophthalmol Vis Sci; 2014 Mar; 55(3):1332-8. PubMed ID: 24481260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function.
    Querques G; Lattanzio R; Querques L; Triolo G; Cascavilla ML; Cavallero E; Del Turco C; Casalino G; Bandello F
    Retina; 2014 Feb; 34(2):330-41. PubMed ID: 23945638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.
    Birch DG; Bernstein PS; Iannacone A; Pennesi ME; Lam BL; Heckenlively J; Csaky K; Hartnett ME; Winthrop KL; Jayasundera T; Hughbanks-Wheaton DK; Warner J; Yang P; Fish GE; Teske MP; Sklaver NL; Erker L; Chegarnov E; Smith T; Wahle A; VanVeldhuisen PC; McCormack J; Lindblad R; Bramer S; Rose S; Zilliox P; Francis PJ; Weleber RG
    JAMA Ophthalmol; 2018 Aug; 136(8):849-856. PubMed ID: 29879277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rates of decline in regions of the visual field defined by frequency-domain optical coherence tomography in patients with RPGR-mediated X-linked retinitis pigmentosa.
    Birch DG; Locke KG; Felius J; Klein M; Wheaton DK; Hoffman DR; Hood DC
    Ophthalmology; 2015 Apr; 122(4):833-9. PubMed ID: 25556114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration.
    Zhang K; Hopkins JJ; Heier JS; Birch DG; Halperin LS; Albini TA; Brown DM; Jaffe GJ; Tao W; Williams GA
    Proc Natl Acad Sci U S A; 2011 Apr; 108(15):6241-5. PubMed ID: 21444807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of topical dorzolamide and ketorolac treatment for cystoid macular edema in retinitis pigmentosa and Usher's syndrome.
    Lemos Reis RF; Moreira-Gonçalves N; Estrela Silva SE; Brandão EM; Falcão-Reis FM
    Ophthalmologica; 2015; 233(1):43-50. PubMed ID: 25428176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The artificial silicon retina microchip for the treatment of vision loss from retinitis pigmentosa.
    Chow AY; Chow VY; Packo KH; Pollack JS; Peyman GA; Schuchard R
    Arch Ophthalmol; 2004 Apr; 122(4):460-9. PubMed ID: 15078662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Macular diseases--application of automated static perimetry and optical coherence tomography].
    Iijima H
    Nippon Ganka Gakkai Zasshi; 2000 Dec; 104(12):943-59. PubMed ID: 11193945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases.
    Kauper K; McGovern C; Sherman S; Heatherton P; Rapoza R; Stabila P; Dean B; Lee A; Borges S; Bouchard B; Tao W
    Invest Ophthalmol Vis Sci; 2012 Nov; 53(12):7484-91. PubMed ID: 23049090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal injection of autologous bone marrow-derived mononuclear cells for hereditary retinal dystrophy: a phase I trial.
    Siqueira RC; Messias A; Voltarelli JC; Scott IU; Jorge R
    Retina; 2011 Jun; 31(6):1207-14. PubMed ID: 21293313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of cataract surgery on optical coherence tomography and neurophysiology measurements in patients with retinitis pigmentosa.
    Garcia-Martin E; Rodriguez-Mena D; Dolz I; Almarcegui C; Gil-Arribas L; Bambo MP; Larrosa JM; Polo V; Pablo LE
    Am J Ophthalmol; 2013 Aug; 156(2):293-303.e2. PubMed ID: 23677138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.